menu
    • menu

    Company profile for Arthrosi Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Arthrosi Therapeutics, Inc. was founded in San Diego, CA, in 2018, by a world-class team of gout experts who spearheaded the clinical development of the first generation of urate inhibitor treatment for gout at Ardea Biosciences resulting in a $1.26 Billion acquisition by AstraZeneca. With its vast therapeutic and treatment knowledge, Arthrosi has efficiently completed multiple robust phase 1 and 2 clinical studies in a mere t...
    Arthrosi Therapeutics, Inc. was founded in San Diego, CA, in 2018, by a world-class team of gout experts who spearheaded the clinical development of the first generation of urate inhibitor treatment for gout at Ardea Biosciences resulting in a $1.26 Billion acquisition by AstraZeneca. With its vast therapeutic and treatment knowledge, Arthrosi has efficiently completed multiple robust phase 1 and 2 clinical studies in a mere two years and accumulated a comprehensive and robust intellectual property portfolio.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Arthrosi TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    9855 Towne Centre Dr Ste 200 San Diego, California, 92121,
    Telephone
    Telephone
    +(1) 858-437-9013
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://arthrosi.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sobi to buy US Biotech Arthrosi for up to $1.5 B
    Sobi to buy US Biotech Arthrosi for up to $1.5 B

    13 Dec 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/swedens-sobi-buy-arthrosi-therapeutics-15-billion-2025-12-13/

    REUTERS
    13 Dec 2025
    Share Share
    Arthrosi Raises $153M, Fueling Dash Toward Phase 3 Gout Data
    Arthrosi Raises $153M, Fueling Dash Toward Phase 3 Gout Data

    08 Oct 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/arthrosi-raises-153m-fueling-dash-toward-phase-3-gout-data-2026

    FIERCE BIOTECH
    08 Oct 2025
    Share Share
    Arthrosi Completes Ph3 Trial Enrollment for Pozdeutinurad in Gout
    Arthrosi Completes Ph3 Trial Enrollment for Pozdeutinurad in Gout

    20 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/arthrosi-therapeutics-achieves-full-enrollment-of-the-second-pivotal-phase-3-trial-of-pozdeutinurad-ar882-in-patients-with-gout-including-those-with-tophaceous-gout-302533793.html

    PR NEWSWIRE
    20 Aug 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search